These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 36264536

  • 1. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H, Greenberg J, Shuster D, Hsu C, Watanabe K, LaCreta F.
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [Abstract] [Full Text] [Related]

  • 2. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K, Kawaguchi N, Ishibashi T, Kubota R, Tada Y, Ogura E.
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [Abstract] [Full Text] [Related]

  • 3. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C, Fan B, Ke A, Le K, Yang H.
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J, Rockich K, Yuska B, Zhou G, Epstein N, Punwani N, Chen X, Yeleswaram S.
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
    Yin W, Dong C, Stevenson A, Lloyd V, Petrillo M, Baratta M, Hui T, Han S.
    Drug Metab Dispos; 2024 Feb 14; 52(3):180-187. PubMed ID: 38123352
    [Abstract] [Full Text] [Related]

  • 10. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects.
    Zhang Z, Gao X, Zhang P, Li Y, Fu M, Lin H, Feng S, Shen K, Yu G, Li X.
    Br J Clin Pharmacol; 2023 Aug 14; 89(8):2561-2568. PubMed ID: 37005376
    [Abstract] [Full Text] [Related]

  • 11. Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.
    Li X, Shelton MJ, Wang J, Meade J, Ruiz-Soto R.
    Clin Pharmacol Drug Dev; 2022 Oct 14; 11(10):1165-1176. PubMed ID: 35560823
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, Jin JY.
    Clin Pharmacokinet; 2016 Nov 14; 55(11):1435-1445. PubMed ID: 27225997
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
    Gaudy A, Atsriku C, Ye Y, MacGorman K, Liu L, Xue Y, Surapaneni S, Palmisano M.
    Eur J Clin Pharmacol; 2021 Feb 14; 77(2):223-231. PubMed ID: 32965548
    [Abstract] [Full Text] [Related]

  • 14. An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.
    Chen J, Li J, Wu J, Song Y, Li L, Zhang J, Dong R.
    Pharmacol Res Perspect; 2024 Aug 14; 12(4):e1252. PubMed ID: 39073244
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
    Barbour AM, Punwani N, Epstein N, Landman R, Cimino E, Yuska B, Wang P, He K, Chen X, Yeleswaram S.
    J Clin Pharmacol; 2019 Dec 14; 59(12):1641-1647. PubMed ID: 31282592
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
    Topletz-Erickson A, Lee A, Rustia EL, Sun H, Mayor JG, Abdulrasool LI, Walker L, Endres CJ.
    Clin Pharmacokinet; 2022 Oct 14; 61(10):1417-1426. PubMed ID: 35931943
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I, Li LY, Jiao J, Hellemans P, Rasschaert F, de Zwart L, Snoeys J, De Meulder M, Mamidi RNVS, Ouellet D.
    Eur J Drug Metab Pharmacokinet; 2020 Feb 14; 45(1):101-111. PubMed ID: 31673875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.